Abstract

SUMMARY Diabetic nephropathy is the leading cause of chronic kidney disease worldwide. The expanding endemic of diabetes, the high risk of premature morbidity and mortality and the incapacity of current therapies to halt progression toward renal failure urges additional treatment modalities. We will review current evidence addressing dietary sodium intake as a key determinant of renin–angiotensin–aldosterone system (RAAS)-blockade efficacy, particularly in diabetic nephropathy. High sodium intake is very common in these patients, and blunts the protective effects of RAAS-blockade on cardiovascular and renal outcomes. Moderate dietary sodium restriction restores the protective effects of RAAS-blockade. The data warrant monitoring of sodium intake and practical implementation of sodium restriction as a lifestyle-related intervention, mandatory as an addition to RAAS-blockade in diabetic nephropathy.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.